Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP1CA | P62136 | 3/20 | 0.70 |
| ▸ | RPA1 | P27694 | 8/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MARS1 | P56192 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765021 | 0.96 | PPP1CA (0.68) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1765005 | 0.93 | RPA1 (0.63) | PPP1CARPA1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL1765063 | 0.89 | PPP1CA (0.82) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1765454 | 0.88 | RPA1 (0.65) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1765538 | 0.88 | PPP1CA (0.63) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1110855 | 0.86 | PPP1CA (0.87) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1765061 | 0.85 | RPA1 (0.62) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1765405 | 0.85 | PPP1CA (0.56) | PPP1CARPA1L3MBTL1MARS1SMN1; SMN2 | |
| SCHEMBL1765263 | 0.84 | RPA1 (0.54) | PPP1CARPA1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL2193884 | 0.84 | TP53 (0.52) | PPP1CASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278965-B1 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-11-13 | — | — | EP | disclosed |
| EP-2278965-B1 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-11-13 | — | — | EP | disclosed |
| US-8314089-B2 | Substituted pyrazolamides and their use | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8314089-B2 | Substituted pyrazolamides and their use | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2278965-A2 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009115252-A2 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115252-A2 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | CACNA1A, P2RX4, KCNH1 | PPP1CA 246/4885RPA1 4677/4885L3MBTL1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.